Healthcare
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses: 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), taking place September 28–October 2
About this update from Century Therapeutics, Inc.
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses: Both presentations will highlight CNTY-813, Century's iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes. EASD 2026 Presentation Details Title: CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC-Derived Islets for Off-the-Shelf Cell Therapies Format: Oral Presentation Presenter: Grant Welstead, PhD, SVP, Head of Research, Century Therapeutics Session: OP 39 – Beta cells on demand: stem cells to beta cell therapy Presentation Number: 225 Date/Time: Friday, October 2, 2026, 10:00–11:00 AM CEST, Paris Hall CRC 2026 Presentation Details Title: CNTY-813: Scalable Production of Allo-Evasion™ 5.0-Engineered iPSC Beta Islets for Off-the-Shelf Cell Therapies Format: Oral Presentation Presenter: Leonardo Velazco-Cruz, PhD, Islet Process Science Session: 0300 - ORALS 01: Cell Therapy Science & Clinical Presentation Number: 341 Date/Time: Friday, October 9, 2026, 3:50-4:50 PM EDT, Hall 1 Additional information about the EASD 2026 Annual Meeting is available on the EASD website , and additional information about the CRC 2026 Congress is available on the CRC website . Both presentations will be made available on Century's website following the session on its presentations tab: Science | Century Therapeutics . About CNTY-813 CNTY-813 is Century's potential iPSC-derived islet replacement therapy for T1D. CNTY-813 is engineered with Allo-Evasion™ 5.0, Century's proprietary immune evasion technology, which is designed to enable durable engraftment without chronic systemic immunosuppression, the central unresolved limitation of every currently approved or late-stage cell therapy approach to T1D. Preclinical data demonstrated robust glucose-responsive function, favorable pre-clinical safety profile, scalable and reproducible manufacturing, and immune protection under alloimmune pressure. Century is targeting an IND submission for CNTY-813 in the fourth quarter of 2026.
View stock analysis, news, and events for Century Therapeutics, Inc.